A Novel Composite Endpoint of Toxicity- and Progression-Free Survival after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma

被引：0

作者：

Mohty, Razan ^{[1
]}

Junmin, Whiting ^{[2
]}

Saha, Aditi ^{[3
]}

Kim, Jongphil ^{[2
]}

Nishihori, Taiga ^{[1
]}

De Avila, Gabriel ^{[4
]}

Corallo, Salvatore ^{[1
]}

Dam, Marian ^{[1
]}

Marin, Jessica ^{[1
]}

Liu, Hien ^{[5
]}

Mokhtari, Sepideh ^{[6
]}

Jain, Michael D. ^{[1
]}

Perna, Fabiana ^{[7
]}

Blue, Brandon ^{[3
]}

Grajales-Cruz, Ariel F. ^{[4
]}

Castaneda, Omar ^{[8
]}

Shain, Kenneth ^{[4
]}

Baz, Rachid ^{[3
]}

Freeman, Ciara Louise L. ^{[8
]}

Alsina, Melissa ^{[5
]}

Locke, Frederick L. ^{[1
,5
]}

Hansen, Doris K.

Lazaryan, Aleksandr ^{[1
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat & Cellular Immun, Tampa, FL USA

[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Biostat & Bioinformat, Tampa, FL USA

[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[6] H Lee Moffitt Canc Ctr & Res Inst, Dept Neurooncol, Tampa, FL USA

[7] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat & Cellular Immun, Indianapolis, IN USA

[8] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-184406

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[31] Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed/refractory large B-cell lymphoma
Lutfi, Forat
Holtzman, Noa
Siglin, Jonathan
Bukhari, Ali
Mustafa Ali, Moaath
Kim, Dong
Sanchez-Petitto, Gabriela
Gottlieb, David
Ruehle, Kathleen
Hutnick, Elizabeth
Gahres, Natalie
Hankey, Kim
Lee, Seung
Kocoglu, Mehmet
Yared, Jean
Hardy, Nancy
Rapoport, Aaron
Dahiya, Saurabh
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 192 (01) : 212 - 216
[32] Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
Hu, Hongxiang
Li, Yan
Piasecki, Julia
Hosseyni, Daniela
Yan, Zhicheng
Liu, Xianghong
Ogasawara, Ken
Zhou, Simon
Cheng, Yiming
CLINICAL CANCER RESEARCH, 2025, 31 (06) : 1163 - 1171
[33] Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma
Chen, Wei
Wang, Ying
Qi, Kunming
Shi, Ming
Cao, Jiang
Bhansali, Rahul
Wang, Xue
Liu, Yang
Li, Hujun
Zhang, Huanxin
Yan, Zhiling
Sang, Wei
Cheng, Hai
Zhu, Feng
Sun, Haiying
Li, Depeng
Jing, Guangjun
Zheng, Junnian
Li, Zhenyu
Xu, Kailin
TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (03): : 273.e1 - 273.e5
[34] Safety and efficacy of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma with renal impairment
Hujun Li
Lingling Yin
Ying Wang
Xiangmin Wang
Ming Shi
Jiang Cao
Zhiling Yan
Wei Sang
Hai Cheng
Feng Zhu
Haiying Sun
Depeng Li
Guangjun Jing
Junnian Zheng
Zhenyu Li
Kailin Xu
Bone Marrow Transplantation, 2020, 55 : 2215 - 2218
[35] Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment
Sidana, Surbhi
Peres, Lauren C.
Hashmi, Hamza
Hosoya, Hitomi
Ferreri, Christopher
Khouri, Jack
Dima, Danai
Atrash, Shebli
Voorhees, Peter
Simmons, Gary
Sborov, Douglas W.
Kalariya, Nilesh
Hovanky, Vanna
Bharadwaj, Sushma
Miklos, David
Wagner, Charlotte
Kocoglu, Mehmet H.
Kaur, Gurbakhash
Davis, James A.
Midha, Shonali
Janakiram, Murali
Freeman, Ciara
Alsina, Melissa
Locke, Frederick
Gonzalez, Rebecca
Lin, Yi
Mcguirk, Joseph
Afrough, Aimaz
Shune, Leyla
Patel, Krina K.
Hansen, Doris K.
HAEMATOLOGICA, 2024, 109 (03) : 777 - 786
[36] Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience
Lal, Bhavesh Mohan
Pandey, Toshali
Alzubi, Marah
Alrawabdeh, Jawad
Shaughnessy Jr, John D.
Zhan, Fenghuang
Siegel, Eric
Schinke, Carolina
Thanendrarajan, Sharmilan
Zangari, Maurizio
van Rhee, Frits
Al Hadidi, Samer
BLOOD, 2024, 144 : 2405 - 2406
[37] Safety and efficacy of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma with renal impairment
Li, Hujun
Yin, Lingling
Wang, Ying
Wang, Xiangmin
Shi, Ming
Cao, Jiang
Yan, Zhiling
Sang, Wei
Cheng, Hai
Zhu, Feng
Sun, Haiying
Li, Depeng
Jing, Guangjun
Zheng, Junnian
Li, Zhenyu
Xu, Kailin
BONE MARROW TRANSPLANTATION, 2020, 55 (11) : 2215 - 2218
[38] Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM)
Theprungsirikul, Poy
Yu, Mansen
Liu, Yuxin
Rall, Kerri
Matthews, Martin
Neparidze, Natalia
Parker, Terri
Browning, Sabrina
Anderson, Tara
Stevens, Erica
Foss, Francine
Gowda, Lohith
Pillai, Manoj
Isufi, Iris
Seropian, Stuart
Mirza, Sayeef
Bar, Noffar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S92 - S93
[39] CAR T-Cell Therapy Against B-Cell Maturation Antigen in Multiple Myeloma
Cohen, Adam D.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (12) : 804 - 806
[40] Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
Timmers, Marijke
Roex, Gils
Wang, Yuedi
Campillo-Davo, Diana
Van Tendeloo, Viggo F., I
Chu, Yiwei
Berneman, Zwi N.
Luo, Feifei
Van Acker, Heleen H.
Anguille, Sebastien
FRONTIERS IN IMMUNOLOGY, 2019, 10

← 1 2 3 4 5 →